Credit: Shutterstock photoNovoCure LimitedNVCR was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company-as the stock is now down 17.3% in the past one-month time frame.
The company has seen a mixed track record when it comes to estimate revision of one increase and two decreases over the past few months, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
NovoCure currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
NovoCure Limited Price
NovoCure Limited Price | NovoCure Limited Quote
Investors interested in the Medical Services industry may consider PRA Health Sciences, Inc. PRAH , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is NVCR going up? Or down? Predict to see what others think: Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NovoCure Limited (NVCR): Free Stock Analysis Report
PRA Health Sciences, Inc. (PRAH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
